Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Consolidated Net Income: 2013-2024

Historic Consolidated Net Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$269.9 million.

  • Viridian Therapeutics, Inc.\DE's Consolidated Net Income rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Consolidated Net Income is -$269.9 million, which was down 13.55% from -$237.7 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Consolidated Net Income registered a high of -$79.4 million during FY2021, and its lowest value of -$269.9 million during FY2024.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Consolidated Net Income value was -$237.7 million (recorded in 2023), while the average stood at -$212.5 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Consolidated Net Income plummeted by 159.00% in 2020 and then climbed by 28.38% in 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Consolidated Net Income (Yearly) stood at -$110.9 million in 2020, then climbed by 28.38% to -$79.4 million in 2021, then crashed by 63.54% to -$129.9 million in 2022, then crashed by 83.05% to -$237.7 million in 2023, then fell by 13.55% to -$269.9 million in 2024.